Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
AUTOR(ES)
Macedo, Gabriel S.
FONTE
Genet. Mol. Biol.
DATA DE PUBLICAÇÃO
29/04/2019
RESUMO
Abstract Germline mutations in BRCA1 and BRCA2 (BRCA) genes confer high risk of developing cancer, especially breast and ovarian tumors. Since the cloning of these tumor suppressor genes over two decades ago, a significant amount of research has been done. Most recently, monoallelic loss-of-function mutations in PALB2 have also been shown to increase the risk of breast cancer. The identification of BRCA1, BRCA2 and PALB2 as proteins involved in DNA double-strand break repair by homologous recombination and of the impact of complete loss of BRCA1 or BRCA2 within tumors have allowed the development of novel therapeutic approaches for patients with germline or somatic mutations in said genes. Despite the advances, especially in the clinical use of PARP inhibitors, key gaps remain. Now, new roles for BRCA1 and BRCA2 are emerging and old concepts, such as the classical two-hit hypothesis for tumor suppression, have been questioned, at least for some BRCA functions. Here aspects regarding cancer predisposition, cellular functions, histological and genomic findings in BRCA and PALB2-related tumors will be presented, in addition to an up-to-date review of the evolution and challenges in the development and clinical use of PARP inhibitors.
Documentos Relacionados
- Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
- Structural basis for recruitment of BRCA2 by PALB2
- Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
- The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
- The role of the doctor in precision medicine